Summary: BlackRock listed distributions per share for multiple funds with estimated sources of the distributions, including net income, net realized short-term gains, net realized long-term gains, and return of capital. The distributions are subject to change based on the discretion of each fund's Board of Directors/Trustees.
Full articleSummary: Chair Gary Gensler has proposed aggressive rulemaking at the SEC, specifically targeting climate-related disclosures by public companies and ESG factors by investment firms. However, the scope of these proposals exceeds the SEC's statutory authority, leading to significant legal challenges and uncertainties.
Full articleSummary: Amgen and Sandoz reached a settlement regarding biosimilar products, allowing Sandoz to enter the U.S. market after certain conditions are met.
Full articleSummary: BlackRock closed-end funds announced distributions for various municipal, taxable fixed income, equity, and multi-asset funds. The funds have adopted managed distribution plans to support a level monthly distribution of income, capital gains, and/or return of capital. The distributions are subject to change based on the discretion of each fund's Board of Directors/Trustees.
Full articleSummary: BlackRock announced distributions for certain closed-end funds. The distributions are part of managed distribution plans to provide a level monthly distribution of income, capital gains, and/or return of capital.
Full articleSummary: BlackRock Released Distributions Per Share for Multiple Funds under Managed Distribution Plan for Consistent Monthly Distributions based on Net Income, Capital Gains, and Return of Capital.
Full articleSummary: BlackRock Resources & Commodities Strategy Trust and other BlackRock Funds paid distributions per share on April 30, 2024. These distributions are part of a managed distribution plan to support level monthly distributions. The funds have estimated sources of distributions paid and for the current fiscal year, mainly consisting of net income and return of capital.
Full articleSummary: Moderna has initiated litigation against BioNTech and Pfizer related to mRNA technology patents. The Patent Trial and Appeal Board of the USPTO has instituted Inter Partes Review for the patents challenged by BioNTech and Pfizer. A final written decision for the Inter Partes Review is expected by March 19, 2025. Judge Richard G. Stearns granted BioNTech and Pfizer's motion to stay the district court litigation pending the resolution of the Inter Partes Review.
Full article